New Minor-HLA for the Diagnostics, Prophylaxis and Therapy of AML Patients

T lymphocytes present HLA molecules on their surface. The allogeneic transplantations of blood cells could lead either to a required graft- versus- leukaemia/ tumor reaction (GvL/T) or could result in an undesired graft-versus-Host-Disease (GvHD). If there is a complete HLA-match, these effects could result from minor histocompatibility antigens. The present invention deals with an unknown mHAg. Studies have shown that T cells from one donor, which were coincubated with leukaemia cells (homozygous for HLA- molecules), could induce specific T cell responses. Accordingly these results refer to an immunogenic mHAg. A minor- mismatch could lead to a GvH- Disease or to positive GvL reactions. In the first case a tissue typing from donor and recipient could minimize the risk of a GvHD. In the second case the preferable GvL-/ GvT- effects could be increased through a transfer of antigen specific T cells or T cell receptors by inoculation.

Further information: PDF

IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50

Contact
Dr. Klaus Kobek

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.